Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling 326,187 shares, a growth of 32.6% from the March 15th total of 246,072 shares. Currently, 8.7% of the company’s stock are short sold. Based on an average daily trading volume, of 393,998 shares, the days-to-cover ratio is presently 0.8 days.

Wall Street Analysts Forecast Growth

ALZN has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alzamend Neuro in a report on Monday, December 29th. Ascendiant Capital Markets dropped their price objective on Alzamend Neuro from $42.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Alzamend Neuro has a consensus rating of “Hold” and an average target price of $28.00.

Alzamend Neuro Trading Up 15.7%

Shares of NASDAQ:ALZN opened at $1.04 on Wednesday. The firm has a 50 day simple moving average of $1.68 and a 200-day simple moving average of $2.05. Alzamend Neuro has a twelve month low of $0.84 and a twelve month high of $8.22. The company has a market capitalization of $3.95 million, a PE ratio of -0.48 and a beta of -0.05.

Alzamend Neuro (NASDAQ:ALZN) last posted its earnings results on Wednesday, March 11th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.05). As a group, equities research analysts predict that Alzamend Neuro will post -1.68 EPS for the current fiscal year.

Institutional Trading of Alzamend Neuro

An institutional investor recently raised its position in Alzamend Neuro stock. Geode Capital Management LLC increased its position in Alzamend Neuro, Inc. (NASDAQ:ALZN) by 33.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 27,506 shares of the company’s stock after purchasing an additional 6,928 shares during the period. Geode Capital Management LLC owned 0.72% of Alzamend Neuro worth $50,000 at the end of the most recent quarter. 49.61% of the stock is currently owned by hedge funds and other institutional investors.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.